HUM - Humana Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
280.00
-0.14 (-0.05%)
As of 11:54AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close279.82
Open280.21
Bid279.87 x 1000
Ask280.02 x 800
Day's Range278.98 - 280.89
52 Week Range261.35 - 355.88
Volume340,062
Avg. Volume1,141,693
Market Cap37.979B
Beta (3Y Monthly)1.05
PE Ratio (TTM)23.03
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.00 (0.71%)
Ex-Dividend Date2018-12-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • Humana, Accolade to Team Up for Providing Advanced Healthcare
    Zacks3 hours ago

    Humana, Accolade to Team Up for Providing Advanced Healthcare

    Humana (HUM) ties up with Accolade to meet healthcare needs of employers and their health plan members.

  • Why is it Worth Keeping Humana (HUM) in Your Portfolio Now?
    Zacks3 days ago

    Why is it Worth Keeping Humana (HUM) in Your Portfolio Now?

    Riding high on robust Medicare business and strategic buyouts, Humana (HUM) looks promising to reap benefits for investors.

  • Humana to pay $500,0000 in pregnancy-discrimination settlement
    American City Business Journals4 days ago

    Humana to pay $500,0000 in pregnancy-discrimination settlement

    Humana Inc. agreed pay $500,000 — plus $250,000 in attorney fees and costs — to settle a pregnancy-discrimination lawsuit. The New Jersey Law Journal reports that a former employee sued the Louisville-based health insurance company, claiming that it unlawfully fired her when she became pregnant. U.S. District Judge Freda Wolfson in New Jersey entered judgment Friday in favor of Kate Jenkins, according to the report.

  • Top Stock Reports for Visa, Honeywell & Biogen
    Zacks4 days ago

    Top Stock Reports for Visa, Honeywell & Biogen

    Top Stock Reports for Visa, Honeywell & Biogen

  • The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

    The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Humana Inc.

    Humana Inc NYSE:HUMView full report here! Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for HUM with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HUM. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold HUM had net inflows of $2.33 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. HUM credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • When Should You Buy Humana Inc. (NYSE:HUM)?
    Simply Wall St.7 days ago

    When Should You Buy Humana Inc. (NYSE:HUM)?

    Let's talk about the popular Humana Inc. (NYSE:HUM). The company's shares received a lot of attention from a substantial price movement on the NYSE over the last few months, increasingRead More...

  • Why Is Humana (HUM) Down 11.7% Since Last Earnings Report?
    Zacks10 days ago

    Why Is Humana (HUM) Down 11.7% Since Last Earnings Report?

    Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Humana CEO compensation dips by nearly 20 percent in 2018
    American City Business Journals11 days ago

    Humana CEO compensation dips by nearly 20 percent in 2018

    The CEO's compensation for 2018 was more than 200 times that of the median employee compensation.

  • Is UnitedHealth a Good Buy Despite Recent Regulatory Noise?
    Zacks12 days ago

    Is UnitedHealth a Good Buy Despite Recent Regulatory Noise?

    The decline in UnitedHealth's (UNH) share price due to the recent legislative events, offers a good buying opportunity.

  • Managed Care Stocks Near Support on 'Medicare-for-All' Bill
    Investopedia13 days ago

    Managed Care Stocks Near Support on 'Medicare-for-All' Bill

    Managed care stocks are approaching support as investors make sense of a proposed "Medicare-for-All" bill. Let's explore three trading ideas.

  • MarketWatch14 days ago

    Health care ETF's 'bearish engulfing' chart pattern warns of an end to the recent uptrend

    The intraday U-turn in the SPDR Health Care Select Sector ETF has produced a "bearish engulfing" reversal chart pattern, which many technicians would say warns that the 2-month uptrend in the sector has ended. The ETF (XLV) opened $93.28, above the Friday's close of $92.95, then rose to a 3-month high of $93.45 in intraday trade before reversing course to close at $91.69, or below Friday's open of $92.22. Candlestick-chart followers believe this pattern suggests that after bears took the bulls' best shot, they launched a successful counterattack that have left bulls retreating. The XLV's decliners Monday were led by shares of managed care companies WellCare Health Plans Inc. , Anthem Inc. and Humana Inc. . Among some downside levels to watch are the 200-day moving average, which currently extends to $89.23, and the 61.8% Fibonacci retracement of the rally off the Dec. 24 closing low to Friday's high, which comes in at $85.38. The XLV has gained 6.0% year to date while the S&P 500 has run up 13.0%.

  • MarketWatch18 days ago

    Medicare for All Act clips managed care and provider stocks for a second day

    Shares of managed care and provider companies slumped for a second-straight session Thursday, in the wake of the introduction of the Medicare-for-All Act to Congress on Wednesday. The bill, introduced by Reps. Pramila Jayapal of Washington, Debbie Dingell of Michigan and others looks for a quick 2-year transition out of employer-sponsored coverage into single-payor Medicare run by the government. Analyst Gary Taylor at J.P. Morgan said he doesn't expect a quick snap-back rally in the managed care and provider stocks this week, but doesn't believe they could rally off lows by summer. He then expects that rally to fade into the second half of the year, as Democratic Presidential debates begin in the fall. Shares of UnitedHealth Group Inc. lost 3% to pace the Dow Jones Industrial Average's decliners, after losing 4.9% on Wednesday; Cigna Corp. sank 3.4%, after falling 4.0% on Wednesday; Humana Inc. shed 1.0% after dropping 4.8% the day before; WellCare Health Plans Inc. slid 3.3% after giving up 3.9% Wednesday; and Anthem Inc. declined 1.8% after losing 3.6% on Wednesday. In comparison, the Dow slipped 0.2% after easing 0.3% the day before.

  • 4 Sickly Healthcare Stocks to Avoid
    InvestorPlace18 days ago

    4 Sickly Healthcare Stocks to Avoid

    U.S. equities are dribbling lower on Thursday as the Trump-Kim summit in Hanoi abruptly ended with no agreement. Adding to the pressure was a batch of weak economic data overnight out of Asia and a stronger-than-expected Q4 GDP report here at home, which could potentially up the pressure on the Federal Reserve to resume its rate hikes.Moreover, the bulls continue to be content with overhead technical resistance near the 2,800 level on the S&P 500 -- a level that has been in play since October.Breath is breaking down a bit here, as traders tighten up positions after a historic start to the year. Healthcare stocks, in particular, are looking vulnerable as politicians once again talk about moving to a single-payer system in the United States.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Best High-Growth Stocks for Young Investors Here are four healthcare stocks to avoid: Cigna (CI)Source: Shutterstock Shares of Cigna (NYSE:CI), a global health insurance company that was the subject of a proposed $47 billion takeover offer from Anthem in 2015 that was rejected on antitrust grounds, is threatening a share price breakdown with a test of the lows seen in December. Shares are already down more than 20%.The company will next report results on May 3 before the bell. Analysts are looking for earnings of $3.71 per share on revenues of $33 billion. When the company last reported on Feb. 1, earnings of $2.46 missed estimates by 3 cents on a 29.3% rise in revenues. United Health Group (UNH)Source: Shutterstock Health plan provider United Health Group (NYSE:UNH) is watching its shares drop below their 200-day moving average in an accelerating breakdown from a recent two-month consolidation range. That marks a loss of 11% from recent levels and 13% from the highs set back in December. Political pressure is building against the health insurance companies, with Democrats in the House calling for Medicare for all, which would effectively end the private insurance market. * 10 Blue-Chip Stocks to Lead the Market The company will next report results on April 16 before the bell. Analysts are looking for earnings of $3.6 per share on revenues of $59.7 billion. When the company last reported on Jan. 15, earnings of $3.28 beat estimates by 6 cents on a 12.2% rise in revenues. CVS Health (CVS)Source: Mike Mozart via FlickrShares of CVS Health (NYSE:CVS) are cratering, down another 0.6% as I write this to cap a loss of nearly 30% from the double-top high near $80 set back in November. The company recently disappointed investors with some downside guidance as investors await the outcome of the of a court decision on the merger with Aetna in a $69 billion deal.The company will next report results on May 22 before the bell. Analysts are looking for earnings of $1.6 per share on revenues of $59.7 billion. When the company last reported on Feb. 20, earnings of $2.1 beat estimates by 8 cents on a 12.5% rise in revenues. Humana (HUM)Source: Shutterstock Shares of health insurer Humana (NYSE:HUM) have broken down below their lower Bollinger Band and 50-day moving average, accelerating a downtrend that looks set to test the January low for a loss of around 7% from here. Shares have already lost more than 18% from the highs seen back in November. Shares were recently initiated with an overnight rating by analysts at Stephens. Poor timing. * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy The company will next report results on May 8 before the bell. Analysts are looking for earnings of $4.3 per share on revenues of $15.7 billion. When the company last reported on Feb. 6, earnings of $2.6 per share beat estimates by 12 cents on a 7.4% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 5 STARS Stocks That Continue to Define the Future * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio * 5 Real Estate Stocks to Buy for Dividend Income Compare Brokers The post 4 Sickly Healthcare Stocks to Avoid appeared first on InvestorPlace.

  • Universal Health's (UHS) Q4 Earnings Beat Estimates, Up Y/Y
    Zacks18 days ago

    Universal Health's (UHS) Q4 Earnings Beat Estimates, Up Y/Y

    Universal Health's (UHS) fourth-quarter results gain from its healthy top-line growth.

  • Humana CEO to sell $7.5M in stock, other execs offload millions
    American City Business Journals21 days ago

    Humana CEO to sell $7.5M in stock, other execs offload millions

    The sales come as Humana's share price is on the rise again after reaching a historic high and a low for the year in the same quarter.

  • Bridges' new leader sees more opportunities for success
    American City Business Journals21 days ago

    Bridges' new leader sees more opportunities for success

    By coordinating care and best practices, the health systems' patients get better care with cost savings all around.

  • Larry Robbins Plunges Into Dan Loeb's Cigna, Buys 3 in 4th Quarter
    GuruFocus.com26 days ago

    Larry Robbins Plunges Into Dan Loeb's Cigna, Buys 3 in 4th Quarter

    Top buys include Third Point manager’s top holding Baxter

  • American City Business Journals26 days ago

    Humana CEO headlines Health Care Heroes with message of health care transformation (EVENT PHOTOS)

    Here's what Bruce Broussard, Humana's CEO and president, had to say at the 2019 Health Care Heroes award banquet on Tuesday night.

  • Despite Its High P/E Ratio, Is Humana Inc. (NYSE:HUM) Still Undervalued?
    Simply Wall St.28 days ago

    Despite Its High P/E Ratio, Is Humana Inc. (NYSE:HUM) Still Undervalued?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! This article is written for those who want to getRead More...

  • InvestorPlacelast month

    UnitedHealth Stock Is a Buy, but Keep an Eye on the External Risks

    The case for insurer UnitedHealth Group (NYSE:UNH) seems almost too easy to make. UNH stock already has been one of the best performers in the market, rising 270% over the past five years. Earnings are expected to grow about 13% in 2019. Yet UnitedHealth stock trades at a seemingly attractive 18x multiple to this year's EPS guidance.With a 10% pullback from early December highs, a cheaper price seems to set up an attractive opportunity. UNH's recent performance and huge earnings growth speak well of management. The company's Optum unit is cutting-edge, and growing revenue while expanding margins. With $226 billion in revenue, meanwhile, UnitedHealth has the scale to serve customers and the size to pressure suppliers.All else equal, I'd expect UnitedHealth stock to keep climbing. Indeed, I recommended UNH a year ago, and even ~15% higher, I'm still bullish. But there are risks here, highlighted by near-term trading in UnitedHealth stock. And investors need to understand those risks before proceeding.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The Case for UnitedHealth StockThis simply seems like a good business. Growth has been phenomenal. The midpoint of 2019 EPS guidance of $14.40-$14.70 suggests a 155% increase from 2014 levels.Obviously, a lower tax rate and acquisitions have provided some outside help. But this is a company operating well, with revenue and margins both rising.UNH has a diversified portfolio, too. It has its hands in seemingly every market, with the insurer serving employers, individuals, Medicare, and state and local governments. The Global segment, built through targeted M&A, is now a $10 billion-plus revenue business.And Optum is at the forefront of changes in the industry. 2018 revenue rose double-digits, and operating margins continued to expand. Other PBMs (pharmacy benefit managers) are struggling. Rite Aid (NYSE:RAD) unit EnvisionRx has disappointed. Express Scripts managed to sell itself to Cigna (NYSE:CI), but at only a modest premium to 2015 highs. In that context, Optum's performance is even more impressive.This seems simply like a very attractive business. It's the largest health insurer in the world. Optum remains a roaring success. And yet UNH stock isn't that expensive, trading at less than 18x the midpoint of FY19 EPS guidance.Double-digit annual EPS growth, a 1.4% dividend and potentially a higher multiple over time mean UnitedHealth could return 10%+ annually for years to come. The Two Key Risks to UNH StockThere are two key risks, however. The first is that competitors are trying to gain scale themselves and expand their reach. Cigna bought out Express Scripts. CVS (NYSE:CVS) acquired Aetna. Rivals are coming after UnitedHealth's market lead.To be fair, larger mergers haven't played out. Cigna and Anthem (NYSE:ANTM) planned to merge back in 2017, but called it off. Aetna and Humana (NYSE:HUM) did the same. But competitors are trying to copy at least some of UnitedHealth's strategy, and their success could make them more formidable foes.The bigger risk is on the political front. UNH stock has struggled in recent sessions after the Trump Administration announced a plan to end drug rebates (which benefit PBMs like Optum). An apparently ham-handed response from Optum, which asked for 21 month's notice of any changes from drug manufacturers, brought some unwanted publicity, and framed Optum as potentially part of the problem - not the solution.From a long term standpoint, UnitedHealth almost certainly can adapt to any changes. But with net margins only just above 5%, even modest pressure on pricing, reimbursements, or other areas of the business can have a big impact on overall profits. And in the short-term, noise around regulatory changes could impact UnitedHealth stock, as appears to have been the case of late. A Matter of TrustAt these levels, at least some of the risks are priced in. And I'd be loath to put too much faith in the federal government, in particular, doing anything to notably change the healthcare model in the U.S.But that could change. A scenario where a Democratic candidate wins the Presidency in 2020 and is backed by a Democratic Congress is far from impossible. Should such a scenario seem plausible next year, UNH stock could start pricing in that risk.Right now, 18x earnings might seem cheap but it's not hard to picture UNH trading at 13-14x (or even worse) if investors believe regulators are coming for the company's margins.The changing political landscape and UnitedHealth's exposure to that landscape, mean this isn't a set-it-and-forget-it stock. Investors need to understand the risks and be willing to be nimble if political risk, in particular, starts to creep up.In the meantime, however, the pullback in UNH stock makes an attractive business available at an enviable price. And that's enough to make UNH a buy - at least for now.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post UnitedHealth Stock Is a Buy, but Keep an Eye on the External Risks appeared first on InvestorPlace.

  • Independent hospital consortium reaches value-based care deal
    American City Business Journalslast month

    Independent hospital consortium reaches value-based care deal

    While specific local numbers weren't available, Humana has about 47,000 Medicare Advantage members in the state.

  • CNBClast month

    Humana executives say Trump's drug rebate proposal would raise premiums, restrict consumer choice

    Trump's new plan to lower drug costs would raise premiums for the broader populations, according to insurance executives. The Trump administration's plan to force insurers to pass on drugmaker discounts to seniors at the pharmacy counter would upend the market and raise consumer premiums in the end, health insurance executives warned investors this week. The Trump administration proposed a ban one week ago on confidential discounts pharmacy benefits management plans negotiate with drugmakers when it comes to government Medicare and Medicaid plans.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of HUM earnings conference call or presentation 6-Feb-19 2:00pm GMT

    Q4 2018 Humana Inc Earnings Call